Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03822208 · ClinicalTrials.gov registry record · Phase 1
First in Human Study for Safety and Tolerability of AL003.
A Phase 1 study, sponsored by Alector.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT03822208: Completed Phase 1 study, sponsored by Alector.
NCT03822208 is a Phase 1 study that has completed, run by Alector. The registered enrollment target is 54 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03822208, a Phase 1 study, has completed, sponsored by Alector.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL003.
Primary Outcome
Incidence of adverse events during the treatment and follow up periods through out the study.
Interventions
- OTHER Saline Solution
- BIOLOGICAL AL003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2019-03-29 |
| Est. Completion | 2021-05-06 |
| Phase | Phase 1 |
What the finished NCT03822208 record still lists
NCT03822208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline Solution is the first listed.
NCT03822208 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03822208 about?
NCT03822208 is a clinical study titled "First in Human Study for Safety and Tolerability of AL003.". This is a multi-center, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmac...
What is the current status of trial NCT03822208?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2019-03-29. Estimated completion is 2021-05-06.
What interventions are being tested in trial NCT03822208?
The interventions under investigation include: Saline Solution (OTHER), AL003 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03822208?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03822208's enrollment target sits among peer trials
54 931st of 2000 higher than 1,053 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI